
Isabelle Koné-paut

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1887659/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis. New England Journal of Medicine, 2012, 367, 2396-2406.	27.0	588
2	Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Annals of the Rheumatic Diseases, 2020, 79, 999-1006.	0.9	400
3	Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Annals of the Rheumatic Diseases, 2013, 72, 678-685.	0.9	350
4	Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis and Rheumatism, 2003, 48, 1093-1101.	6.7	343
5	Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. New England Journal of Medicine, 2018, 378, 1908-1919.	27.0	327
6	SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020. Eurosurveillance, 2020, 25, .	7.0	246
7	Recommendations for the management of autoinflammatory diseases. Annals of the Rheumatic Diseases, 2015, 74, 1636-1644.	0.9	239
8	Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. Annals of the Rheumatic Diseases, 2015, 74, 2043-2049.	0.9	180
9	Interleukin-1 Targeting Drugs in Familial Mediterranean Fever: A Case Series and a Review of the Literature. Seminars in Arthritis and Rheumatism, 2011, 41, 265-271.	3.4	178
10	Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). Annals of the Rheumatic Diseases, 2017, 76, 942-947.	0.9	175
11	Consensus classification criteria for paediatric Behçet's disease from a prospective observational cohort: PEDBD. Annals of the Rheumatic Diseases, 2016, 75, 958-964.	0.9	169
12	Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Annals of the Rheumatic Diseases, 2015, 74, 635-641.	0.9	145
13	European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Annals of the Rheumatic Diseases, 2017, 76, 1788-1796.	0.9	139
14	Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet Journal of Rare Diseases, 2015, 10, 19.	2.7	117
15	Behçet's disease in children, an overview. Pediatric Rheumatology, 2016, 14, 10.	2.1	111
16	ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Annals of the Rheumatic Diseases, 2018, 77, 1003-1011.	0.9	110
17	Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments. Seminars in Arthritis and Rheumatism, 2017, 47, 115-120.	3.4	108
18	Autoinflammatory diseases. Best Practice and Research in Clinical Rheumatology, 2008, 22, 811-829.	3.3	107

#	Article	IF	CITATIONS
19	European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Annals of the Rheumatic Diseases, 2017, 76, 1965-1973.	0.9	105
20	The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry. Rheumatology, 2018, 57, 1203-1211.	1.9	105
21	European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease – the SHARE initiative. Rheumatology, 2019, 58, 672-682.	1.9	103
22	The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: A retrospective cases series. Autoimmunity Reviews, 2018, 17, 768-774.	5.8	94
23	European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides – the SHARE initiative. Rheumatology, 2019, 58, 656-671.	1.9	77
24	Incidence of IgA vasculitis in children estimated by four-source capture–recapture analysis: a population-based study. Rheumatology, 2017, 56, 1358-1366.	1.9	75
25	Development of the autoinflammatory disease damage index (ADDI). Annals of the Rheumatic Diseases, 2017, 76, 821-830.	0.9	68
26	A decision tree for the genetic diagnosis of deficiency of adenosine deaminase 2 (DADA2): a French reference centres experience. European Journal of Human Genetics, 2018, 26, 960-971.	2.8	65
27	Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients. Journal of Autoimmunity, 2018, 91, 55-60.	6.5	59
28	Performance of Different Diagnostic Criteria for Familial Mediterranean Fever in Children with Periodic Fevers: Results from a Multicenter International Registry. Journal of Rheumatology, 2016, 43, 154-160.	2.0	52
29	Review: Found in Translation: International Initiatives Pursuing Interleukinâ€1 Blockade for Treatment of Acute Kawasaki Disease. Arthritis and Rheumatology, 2017, 69, 268-276.	5.6	51
30	Phase II Open Label Study of Anakinra in Intravenous Immunoglobulin–Resistant Kawasaki Disease. Arthritis and Rheumatology, 2021, 73, 151-161.	5.6	51
31	IL-1 Inhibition May Have an Important Role in Treating Refractory Kawasaki Disease. Frontiers in Pharmacology, 2017, 8, 163.	3.5	47
32	Targeting interleukin-1β in CAPS (cryopyrin-associated periodic) syndromes. Autoimmunity Reviews, 2012, 12, 77-80.	5.8	46
33	Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases. Annals of the Rheumatic Diseases, 2019, 78, 1405-1411.	0.9	44
34	Anakinra for cryopyrin-associated periodic syndrome. Expert Review of Clinical Immunology, 2014, 10, 7-18.	3.0	41
35	Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial. Annals of the Rheumatic Diseases, 2020, 79, 1362-1369.	0.9	39
36	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. Annals of the Rheumatic Diseases, 2021, 80, 698-706.	0.9	37

#	Article	IF	CITATIONS
37	Defining the risk of first intravenous immunoglobulin unresponsiveness in non-Asian patients with Kawasaki disease. Scientific Reports, 2020, 10, 3125.	3.3	36
38	Rapid and Sustained Longâ€Term Efficacy and Safety of Canakinumab in Patients With Cryopyrinâ€Associated Periodic Syndrome Ages Five Years and Younger. Arthritis and Rheumatology, 2019, 71, 1955-1963.	5.6	34
39	Pediatric Inflammatory Multisystem Syndrome and Rheumatic Diseases During SARS-CoV-2 Pandemic. Frontiers in Pediatrics, 2020, 8, 605807.	1.9	34
40	Time to diagnosis in juvenile idiopathic arthritis: a french perspective. Orphanet Journal of Rare Diseases, 2017, 12, 43.	2.7	33
41	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmunity Reviews, 2017, 16, 650-657.	5.8	32
42	A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever. Orphanet Journal of Rare Diseases, 2017, 12, 54.	2.7	32
43	Is it Kawasaki shock syndrome, Kawasaki-like disease or pediatric inflammatory multisystem disease? The importance of semantic in the era of COVID-19 pandemic. RMD Open, 2020, 6, e001333.	3.8	32
44	Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach. Rheumatology, 2021, 60, 3799-3808.	1.9	29
45	Neurological outcome of patients with cryopyrin-associated periodic syndrome (CAPS). Orphanet Journal of Rare Diseases, 2017, 12, 33.	2.7	28
46	In silico validation of the Autoinflammatory Disease Damage Index. Annals of the Rheumatic Diseases, 2018, 77, 1599-1605.	0.9	27
47	French recommendations for the management of Behçet's disease. Orphanet Journal of Rare Diseases, 2021, 16, 352.	2.7	27
48	Coronary artery abnormalities in children with systemic-onset juvenile idiopathic arthritis. Joint Bone Spine, 2014, 81, 257-259.	1.6	26
49	Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. Rheumatology, 2022, 61, 1376-1384.	1.9	26
50	2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. Annals of the Rheumatic Diseases, 2022, 81, 34-40.	0.9	26
51	Retrospective Study Evaluating Treatment Decisions and Outcomes of Childhood Uveitis Not Associated with Juvenile Idiopathic Arthritis. Journal of Pediatrics, 2017, 186, 131-137.e1.	1.8	25
52	A restrospective survey of patients's journey before the diagnosis of mevalonate kinase deficiency. Joint Bone Spine, 2015, 82, 240-244.	1.6	24
53	Health-related quality of life in children with PFAPA syndrome. Orphanet Journal of Rare Diseases, 2018, 13, 132.	2.7	24
54	Delineating phenotypes of Kawasaki disease and SARS-CoV-2-related inflammatory multisystem syndrome: a French study and literature review. Rheumatology, 2021, 60, 4530-4537.	1.9	24

#	Article	IF	CITATIONS
55	EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021. Annals of the Rheumatic Diseases, 2023, 82, 35-47.	0.9	23
56	A novel assessment tool for clinical care of patients with autoinflammatory disease: juvenile autoinflammatory disease multidimensional assessment report. Clinical and Experimental Rheumatology, 2016, 34, 129-135.	0.8	22
57	Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open‣abel, Activeâ€Treatment Extension Study. Arthritis and Rheumatology, 2020, 72, 2147-2158.	5.6	21
58	New data in causes of autoinflammatory diseases. Joint Bone Spine, 2019, 86, 554-561.	1.6	17
59	An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptor–associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. Journal of Rheumatology, 2019, 46, 429-436.	2.0	16
60	The European network for care of children with paediatric rheumatic diseases: care across borders. Rheumatology, 2019, 58, 1188-1195.	1.9	15
61	Realâ€World Experience and Impact of Canakinumab in Cryopyrinâ€Associated Periodic Syndrome: Results From a French Observational Study. Arthritis Care and Research, 2017, 69, 903-911.	3.4	14
62	Standard dose of Ustekinumab for childhood-onset deficiency of interleukin–36 receptor antagonist. Annals of the Rheumatic Diseases, 2018, 77, e88-e88.	0.9	14
63	DADA2 diagnosed in adulthood versus childhood: A comparative study on 306 patients including a systematic literature review and 12 French cases. Seminars in Arthritis and Rheumatism, 2021, 51, 1170-1179.	3.4	14
64	Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2019, 46, 1117-1126.	2.0	13
65	SARS-CoV-2-associated Henoch–Schönlein purpura in a 13-year-old girl. Archives De Pediatrie, 2021, 28, 573-575.	1.0	12
66	Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases, 2022, 81, 998-1005.	0.9	12
67	Boundaries between familial Mediterranean fever and juvenile spondyloarthritis: Analysis of three French retrospective cohorts. Joint Bone Spine, 2018, 85, 733-739.	1.6	11
68	Longterm Followup of Quality of Life in Patients with Cryopyrin-associated Periodic Syndrome Treated with Canakinumab, an Anti-interleukin 1β Monoclonal Antibody. Journal of Rheumatology, 2014, 41, 1721-1722.	2.0	10
69	The French paediatric cohort of Castleman disease: a retrospective report of 23 patients. Orphanet Journal of Rare Diseases, 2020, 15, 95.	2.7	10
70	Adult-onset Still's disease or systemic-onset juvenile idiopathic arthritis and spondyloarthritis: overlapping syndrome or phenotype shift?. Rheumatology, 2022, 61, 2535-2547.	1.9	10
71	Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative. Annals of the Rheumatic Diseases, 2018, 77, 319-327.	0.9	9
72	Response to: â€~Correspondence on â€~Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID19): a multicentre cohort'' by Mastrolia <i>et al</i> . Annals of the Rheumatic Diseases, 2022, 81, e219-e219.	0.9	9

#	Article	IF	CITATIONS
73	Chronic hepatic involvement in the clinical spectrum of A20 haploinsufficiency. Liver International, 2021, 41, 1894-1900.	3.9	9
74	ls gene panel sequencing more efficient than clinical-based gene sequencing to diagnose autoinflammatory diseases? A randomized study. Clinical and Experimental Immunology, 2020, 203, 105-114.	2.6	8
75	Long-Term Follow-Up and Optimization of Interleukin-1 Inhibitors in the Management of Monogenic Autoinflammatory Diseases: Real-Life Data from the JIR Cohort. Frontiers in Pharmacology, 2020, 11, 568865.	3.5	7
76	The impact of the Eurofever criteria and the new InFevers MEFV classification in real life: Results from a large international FMF cohort. Seminars in Arthritis and Rheumatism, 2022, 52, 151957.	3.4	7
77	COVID-19 infection among patients with autoinflammatory diseases: a study on 117 French patients compared with 1545 from the French RMD COVID-19 cohort: COVIMAI – the French cohort study of SARS-CoV-2 infection in patient with systemic autoinflammatory diseases. RMD Open, 2022, 8, e002063.	3.8	7
78	Alagille Syndrome and Chronic Arthritis: An International Case Series. Journal of Pediatrics, 2020, 218, 228-230.e1.	1.8	5
79	How to handle the main drugs to treat autoinflammatory disorders and how we treat common autoinflammatory diseases. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 574-589.	0.8	4
80	An Immunological Axis Involving Interleukin 1β and Leucine-Rich-α2-Glycoprotein Reflects Therapeutic Response of Children with Kawasaki Disease: Implications from the KAWAKINRA Trial. Journal of Clinical Immunology, 2022, 42, 1330-1341.	3.8	4
81	Burden of illness in hereditary periodic fevers: a multinational observational patient diary study. Clinical and Experimental Rheumatology, 2020, 38 Suppl 127, 26-34.	0.8	3
82	POS1183â€OUTCOMES OF COVID-19 INFECTION AMONG CHILDREN AND YOUNG PEOPLE WITH PRE-EXISTING RHEUMATIC AND MUSCULOSKELETAL DISEASES. Annals of the Rheumatic Diseases, 2021, 80, 872.2-873.	0.9	2
83	Still's Disease in the Constellation of Hyperinflammatory Syndromes: A Link with Kawasaki Disease?. Journal of Clinical Medicine, 2021, 10, 3244.	2.4	2
84	Juvenile Idiopathic Arthritis and COVID-19 Pandemic: Good Compliance With Treatment, Reluctance to Return to School. Frontiers in Medicine, 2021, 8, 743815.	2.6	2
85	THU0579â€Treating To Target with Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis: Results from The Long-Term Extension The Phase III Pivotal Trial. Annals of the Rheumatic Diseases, 2016, 75, 401.2-402.	0.9	1
86	Tattooing and autoinflammatory diseases: a study among 197 French patients from the JIR cohort. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	1
87	FRI0346â€PED-BD, cohort study for paediatric behÇet's disease: Update 2012 reporting 206 patients. Annals of the Rheumatic Diseases, 2013, 71, 431.2-431.	0.9	0
88	THU0294â€Regulatory T cells/TH17 balance in the pathogenesis of pediatric behçet disease. Annals of the Rheumatic Diseases, 2013, 71, 255.1-255.	0.9	0
89	AB0914â€Patient Education in Pediatric Rheumatology: A French Experience. Annals of the Rheumatic Diseases, 2014, 73, 1102.3-1102.	0.9	0
90	AB0991â€Current State of Musculoskeletal Ultrasound in JIA in France and Switzerland. Annals of the Rheumatic Diseases, 2015, 74, 1230.1-1230.	0.9	0

#	Article	IF	CITATIONS
91	THU0562â€A Survey of Resistance To Colchicine Treatment in French Patients with Familial Mediterranean Fever. Annals of the Rheumatic Diseases, 2016, 75, 395.1-395.	0.9	0
92	Autoinflammation secondaire à des défauts d'ubiquitination dans la voie NFKBÂ: haploinsuffisance de A20 (HA20) et déficit en Otuline (Otulinopénie). Revue Du Rhumatisme (Edition Francaise), 2019, 86, 358-366.	0.0	0
93	SAT0514â€MIRAJE: A TRANSVERSAL THERAPEUTIC EDUCATION PROGRAM FOR CHILDREN AND ADOLESCENTS WITH CHRONIC INFLAMMATORY RHEUMATISM. , 2019, , .		0
94	THU0535â€NATURE AND IMPACT OF THE FRENCH NETWORK RESRIP ON SCHOOLING, FOR CHILDREN WITH CHRONIC INFLAMMATORY RHEUMATISM. , 2019, , .		0
95	AB1071â€AUTO-IMMUNE AND INFLAMMATORY DISEASES IN CHILDREN WITH SICKLE CELL DISEASE: DIAGNOST AND THERAPEUTIC ISSUES. , 2019, , .	-IC	0
96	SAT0488â€THE FRENCH PAEDIATRIC COHORT OF CASTLEMAN DISEASE. , 2019, , .		0
97	A tribute to Dr. Tomisaku Kawasaki (7 February 1925–5 June 2020). Archives De Pediatrie, 2020, 27, 283-285.	1.0	0
98	Correspondance on â€~Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases'. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-219566.	0.9	0
99	POS1314â€JUVENILE IDIOPATHIC ARTHRITIS IN THE CONTEXT OF THE CORONAVIRUS DISEASE 19 PANDEMIC: IMPACT ON THE DECREASE IN TREATMENT AND THE RETURN TO SCHOOL. Annals of the Rheumatic Diseases, 2021, 80, 939.2-940.	0.9	0
100	OP0164â€LONG-TERM SAFETY OF ANAKINRA IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS FR THE PHARMACHILD REGISTRY. Annals of the Rheumatic Diseases, 2021, 80, 98.2-99.	OM 0.9	0
101	Editorial: Pathogenesis, Clinical Findings, and Treatment Advances in Kawasaki Disease. Frontiers in Pediatrics, 2021, 9, 781842.	1.9	0
102	When extended genetics rescues diagnosis: a patient with CANDLE-like phenotype and de novo mutation in the <i>SAMD9L</i> gene. Annals of the Rheumatic Diseases, 2022, 81, 447-448.	0.9	0